Direct-acting antivirals were approved for the treatment of hepatitis C virus (HCV) in the US in 2011 and in 2012 in Canada. These drugs are expensive, accounting for the second- and fourth-highest proportion of public drug spending in 2017 for Canada and the US, respectively.
Canada and the US have similar rates of HCV infection among their populations, yet public drug expenditures on HCV medications differ between both countries. This case-study explores differences in drug spending between Canada and the US to compare drug expenditures on HCV medications.
Access the full article and associated resources:
